What changed in this filing

/stocks — the workspaceLOADING

Item 7. Management’s Discussion and Analysis

2024-02-28 compared with 2023-03-14 · 441 added, 693 removed, 85 unchanged (93% of the section changed)

Management’s Discussion and Analysis

of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and

results of operations should be read in conjunction with our Consolidated financial statements and the accompanying notes included elsewhere

in this Annual Report on Form 10-K.

The discussion and analysis below contain certain forward-looking statements about our business and

operations that are subject to the risks, uncertainties, and other factors described in the section entitled “Risk Factors,”

included in Part I, Item 1A, and other factors included elsewhere in this Annual Report on Form 10-K.

These risks, uncertainties, and

other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and the accompanying notes included elsewhere in this Annual Report.

The discussion and analysis below contain certain forward-looking statements about our business and operations that are subject to the risks, uncertainties and other factors described in the section entitled “Risk Factors,” included in Part I, Item 1A, and other factors included elsewhere in this Annual Report.

These risks, uncertainties and other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements.

Please refer to the section entitled “Cautionary Note Regarding Forward-Looking Statements.”

Unless the context requires otherwise, references to “DocGo,”

“we,” “us,” “our” and “the Company” in this section are to the business and operations

of DocGo and its consolidated subsidiaries, including those periods prior to the Business Combination.

Certain figures, such as interest

rates and other percentages, included in this section have been rounded for ease of presentation.

Percentage figures included in this

section have, in some cases, been calculated on the basis of such rounded figures.

For this reason, percentage amounts in this section

may vary slightly from those obtained by performing the same calculations using the figures in DocGo’s Consolidated Financial Statements

or in the associated text.

Certain figures included in this section, such as interest rates and other percentages, have been rounded for ease of presentation.

Percentage figures included in this section have, in some cases, been calculated on the basis of such rounded figures.

For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in our Consolidated Financial Statements or in the associated text.

Certain other amounts that appear in this section may similarly not sum due to rounding.

which was originally formed in 2015, is a healthcare transportation and mobile services company that uses proprietary dispatch and

communication technology to help provide quality healthcare transportation and mobile services in-person medical treatment

directly to patients in the comfort of their homes, workplaces and other non-traditional locations, in major metropolitan

cities in the United States and the United Kingdom.

Company derives revenue primarily from its two operating segments:

Transportation Services and Mobile Health Services.

DocGo is a mobile healthcare services company that uses proprietary dispatch and communication technology to help provide quality mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations;

and medical transportation in major metropolitan cities in the United States and the United Kingdom.

The Company derives revenue primarily from two operating segments:

• Mobile Health Services:

The services offered by this segment include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts.

This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter.

• Transportation Services:

2 unchanged sentences

Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.

Mobile Health Services:

The services offered by this segment include a wide variety of healthcare services performed at home and offices, testing, vaccinations and event services which include on-site healthcare support at sporting events and concerts.

“Business” in this Annual Report on Form 10-K

for additional information regarding DocGo’s business.

the year ended December 31, 2022 the Company recorded net income of $30.7 million, compared to net income of $19.2 million in

the year ended December 31, 2021.

The spread of COVID-19 and the related shutdowns and restrictions had

a mixed impact on our business.

In the Transportation Services segment, which comprises primarily of non-emergency medical transport,

the Company saw a decline in volumes from historical and expected levels, as elective surgeries and other non-emergency surgical procedures

were postponed.

In addition, in the Mobile Health segment, the Company experienced lost revenue associated with sporting, concerts and

other events, as those events were cancelled or had a significantly restricted (or entirely eliminated) number of permitted attendees.

Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There are two areas where the Company experienced positive business

impacts from COVID-19.

In April and May 2020, the Company participated in an emergency project with Federal Emergency Management Agency

in the New York City area.

This engagement resulted in incremental transportation revenue that partially offset some of the lost non-emergency

transport revenues.

In addition, in response to the need for widespread COVID-19 testing and available EMTs and paramedics, the Company

expanded its operations to include Rapid Reliable Testing (“RRT”), with the goal of performing COVID-19 tests at nursing homes,

municipal sites, businesses, schools and other venues.

RRT is part of the Mobile Health business line.

Mobile Health generated approximately

$325.9 million in revenue in the year ended December 31, 2022, as compared to $234.4 million in 2021 and $30.9 million in 2020.

COVID-19 testing has become a minor part of this segment’s business, as of the second half of 2022, the Mobile Health segment has

continued to grow.

We have expanded our service offerings in this segment to offer a wider range of testing, vaccination and other services

to a broader customer group.

During 2020 and the early part of 2021, the Company continued to operate

with several back-office employees working remotely.

During that time, the Company did not witness any significant reduction in productivity

from these employees, nearly all of whom returned to their respective offices and other locations by early 2021 and our operations have

proceeded without major interruption.

DocGo also utilized several government programs in 2020 related to the pandemic, receiving approximately

$1.0 million in payments through the Public Health and Social Services Emergency Fund authorized under the Coronavirus Aid, Relief and

Economic Security Act and related legislation as well as various state and local programs.

DocGo also received accelerated Medicare payments

of approximately $2.4 million that were repaid in 2022.

As the COVID-19 pandemic reaches endemic stages, the future impacts

of it or other pandemics on DocGo remain highly uncertain and subject to numerous factors, including the severity of any new outbreaks,

resurgences and variants, actions taken to contain resurgences or variants or to address their impact, and other effects, and its related

impact on medical transportation levels remain uncertain.

However, trip volumes in most of our markets returned to more normal historical

levels in 2021, and this trend continued throughout 2022.

The Company generated, during 2021, COVID-19 testing revenue, included in its

Mobile Health services segment, above the levels projected, and this persisted through the second quarter of 2022.

However, as expected,

COVID-19 testing revenues declined in the third quarter of 2022 and declined further in the fourth quarter, to the point where, as of

the date of the filing of this Annual Report on Form 10-K, they account for an insignificant proportion of total revenues.

Given the nature

of the Company’s contracts with most of its customers, which include multiple procedures for which the Company is paid per hours

worked, per vehicles and related equipment utilized and on a per-procedure basis (such procedures including both testing and several other

procedures), it is difficult to determine the revenues that are directly attributable to COVID-19 testing.

However, the Company estimates

that COVID-19 testing revenue will continue to account for an insignificant proportion of Mobile Health segment and overall consolidated

revenues in 2023 and beyond, as COVID-19 enters the endemic phase.

In a broader, strategic sense, the consumer focus on Mobile Health

services and the formation of RRT, and its emergence as a significant contributor to overall revenues, have accelerated the diversification

in the Company’s business by more rapid expansion of the Mobile Health segment, which has now become our larger operating segment,

both in terms of revenues and personnel.

The Company’s current business plan assumes an increased demand

for Mobile Health services, a demand that was accelerated by the pandemic, but which we believe is also being driven by longer-term secular

factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s

offices and hospitals.

In the Transportation segment, volumes are expected to continue to rise, reflecting an aging population in the

and U.K., which tends to drive demand for the non-emergent medical transportation services provided by the Company.

Factors Affecting

Our Results of Operations

Our operating results and financial performance are influenced by a

variety of factors, including, among others, our ability to obtain or maintain operating licenses;

the success of our acquisition strategy;

See Item 1, “Business” in this Annual Report for additional information regarding DocGo’s business.

For the year ended December 31, 2023 the Company recorded net income of $10.0 million, compared to net income of $30.7 million and $19.2 million in the years ended December 31, 2022 and 2021, respectively.

Factors Affecting Our Results of Operations

Our operating results and financial performance are influenced by a variety of factors, including, among others, our ability to establish, maintain and grow customer relationships;

our ability to execute projects to the satisfaction of our customers;

conditions in the healthcare transportation and mobile health services markets;

our competitive environment;

overall macroeconomic and

geopolitical conditions, including rising interest rates, the inflationary environment, the potential recessionary environment, regional

conflict and tensions;

availability of healthcare professionals;

changes in government spending on healthcare and other social services;

availability of healthcare professionals and other personnel;

changes in the cost of labor;

and production schedules of our suppliers.

Some of these important factors are briefly discussed below.

Future revenue growth and improvement in operating results will be largely

contingent on DocGo’s ability to penetrate new markets and further penetrate existing markets, which is subject to a number of uncertainties,

many of which are beyond DocGo’s control.

The COVID-19 pandemic also significantly impacted DocGo’s business, as discussed

While the direct impact of the pandemic itself has waned, other impacts, such as supply chain disruptions and the cost and availability

of labor are expected to persist.

Operating Licenses

has historically pursued a strategy to apply for ambulance operating licenses in the states, counties and cities, identified for future

new market entry.

The approval of a new operating license may take an extended period of time.

DocGo reduces this risk through its acquisition

strategy by identifying businesses and/or underlying licenses in these new markets that may be for sale.

DocGo pursued an acquisition strategy to obtain ambulance operating licenses from small operators.

Future acquisitions may also

include larger companies that may help drive revenue, profitability, cash flow and stockholder value, in both the Mobile Health and

the Transportation segments.

During the twelve months ended December 31, 2022, DocGo completed five acquisitions, for a

purchase price of $69.1 million.

On July 6, 2022, the Company acquired Government Medical Services,

LLC (“GMS”) in exchange for $20.3 million in cash and up to a total of $3.0 million in future contingent consideration upon

GMS meeting certain performance conditions .

GMS is in the business of providing licensed healthcare clinicians.

We believe this

acquisition will allow us to increase our presence in that market, while giving us improved access to municipal contracts.

On July 13, 2022, the Company acquired Exceptional Medical Transportation,

LLC (“Exceptional”) in exchange for $7.7 million in cash (and a total of $6.0 million deferred consideration).

Company also agreed to pay an estimated $1.1 million contingent consideration upon Exceptional meeting certain performance conditions.

Exceptional is in the business of providing medical transportation services in New Jersey.

We believe this acquisition will allow us to

increase our presence in that market.

On August 9, 2022, the Company acquired Ryan Brothers Ambulance Inc.

(“RB”), in exchange for $7.4 million of cash (and a total of $4 million in future contingent consideration).

Ryan Brothers

is in the business of providing medical transportation services in Wisconsin.

We believe this acquisition will allow us to increase our

presence in that market.

October 12, 2022, the Company acquired Community Ambulance Services LTD (“CAS”) in exchange for approximately $5.5

million in cash.

CAS is located in the U.K.

and is engaged in providing emergency and non-emergency transport

services, including high dependency, urgent care, mental health and blue light transport services and diagnostics testing.

that this acquisition will help allow us to continue to grow our presence in the U.K.

On December 9, 2022, Ambulnz

Ltd., a wholly owned subsidiary of the Company acquired Location Medical Services, LLC (“LMS”) for a total of $11.6 million

in cash (of which $11.3 million is deferred consideration) and $2.5 million in future contingent consideration.

LMS, based in Shepperton,

U.K., provides professional medical support services, including staff and equipment, for events (festivals, equestrian, cycling, etc.),

as well as for the film and television production industry.

LMS has a staff of over 250 medical professionals.

We believe that this acquisition

will allow us to increase our share of the events business in the U.K.

During the twelve months ended December 31, 2021, DocGo completed

one acquisition, for a purchase price of $2.3 million.

our competitive environment;

overall macroeconomic and geopolitical conditions, including rising interest rates, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S.

federal government;

production schedules of our suppliers;

our ability to obtain or maintain operating licenses;

and the success of our acquisition strategy.

Some of these key factors are briefly discussed below.

Future revenue growth and improvement in operating results will be largely contingent on our ability to penetrate new markets and further penetrate existing markets, which is subject to a number of uncertainties, many of which are beyond our control.

Healthcare Services Market

The transportation services market is highly dependent on patients

requiring transportation after surgeries and other medical procedures and treatments.

During the pandemic, DocGo experienced a decrease

in transportation volumes as a result of fewer elective surgeries.

However, since 2021, the Company has seen increased demand and trip

volumes in nearly all of its Transportation services markets, as elective surgeries resumed and as the Company expanded its customer base.

The Mobile Health Services market is dependent on several factors, including increased patient acceptance of services that are provided outside of traditional healthcare facilities, such as in homes, businesses or other designated locations;

healthcare coverage of the various Mobile Health Services;

and continued desire on the part of government and municipal entities to fund programs to assist currently underserved patient segments via “population health” programs.

These programs increased in number, scale and scope since the beginning of the COVID-19 pandemic.

While COVID-19 testing and vaccination programs have been dramatically scaled back from their levels at the pandemic’s peak, there have been expansions of these population health programs into other areas, such as the provision of healthcare and related services to recent migrants and asylum seekers.

The Transportation Services market is highly dependent on patients requiring transportation after surgeries and other medical procedures and treatments.

The Company primarily focuses on the non-emergency medical transport market, which includes services that are provided to patients who need assistance getting to and from medical appointments.

Key drivers of this market are the increase in chronic conditions and the number of elective surgeries as well as the ongoing aging of the population, as older demographics tend to be much more frequent consumers of medical transportation services.

The market will also grow if hospitals and other healthcare facilities continue to outsource more of their transportation needs to independent providers, such as the Company, allowing these facilities to concentrate their efforts on their core competencies.

Overall Economic Conditions in the Markets in Which We Operate

changes both nationally and locally in our markets impact our financial performance.

Unfavorable changes in demographics, health care

coverage of transportation and mobile health services, interest rates, ambulance manufacturing, a weakening of the national economy or

of any regional or local economy in which we operate and other factors beyond our control could adversely affect our business.

Trip Volumes and Average

“trip” is defined as an instance where the Company completes the transport of a patient to a specific destination, for which

we are able to charge a fee.

This metric does not include instances where a trip is ordered and subsequently either canceled (by the customer)

or declined (by the Company).

As trip volume represents the most basic unit of transportation service provided by the Company, it is the

best measure of the level of demand for the Company’s Transportation services, and is used by management to monitor and manage the

scale of the business.

average trip price is calculated by dividing the aggregate revenue from completed transports (“trips”) by the total number

of transports, and is an important indicator of the effective rate at which the Company is being compensated for its provision of Transportation

generated from programs under which DocGo is paid a fixed rate for the use of a fully staffed and equipped ambulance do not factor in

the trip counts or average trip prices mentioned above.

We anticipate that these fixed rate, “leased hour” programs will account

for an increasing proportion of the Transportation segment’s revenues in the future.

Economic changes, both nationally and locally, in our markets impact our financial performance.

Unfavorable changes in demographics, healthcare coverage of Mobile Health Services and Transportation Services, interest rates, inflation rates, ambulance manufacturing, a weakening of the national economy or of any regional or local economy in which we operate and other factors beyond our control could adversely affect our business.

Our Ability to Control Expenses

We pay close attention to managing our working capital and operating

Some of our most significant operating expenses are labor costs, medical supplies and vehicle-related costs, such as fuel,

maintenance, repair and insurance.

Insurance costs include premiums paid for coverage as well as reserves for estimated losses within

the Company’s insurance policy deductibles.

We aim to employ our proprietary technology to drive improvements in productivity per

We regularly analyze our workforce productivity with a goal of balancing the optimum, cost-efficient labor mix for our

Beginning in March 2021, the inflation rate in the US, as measured

by the Consumer Price Index (CPI) has generally trended higher.

This data is reported monthly, showing year-over-year changes in prices

across a basket of goods and services.

The monthly 12-month inflation rate was 2.6% in March 2021, and increased steadily over the rest

of 2021 and into 2022, with the inflation rate hitting 9.1% in June 2022.

The inflation rate has seemingly moderated since that point,

declining to 6.4% in January 2023, but remains well above historical averages.

On an annual basis, in 2019, the inflation rate was approximately

1.8%, while it dropped to approximately 1.2% in 2020, rising to 4.7% in 2021 and 8.0% in 2022.

The increased inflation rate has had an

impact on the Company’s expenses in several areas, including wages, fuel and medical and other supplies.

This has had the impact

of compressing gross profit margins, as the Company is generally unable to pass these higher costs on to its customers, particularly in

the short term.

In an attempt to dampen inflation, the U.S.

Federal Reserve implemented seven interest rate hikes in 2022, and another

hike to date in 2023, raising its benchmark rate (the “federal funds rate”) from near 0.00%% at the beginning of 2022 to the

current level of 4.50%-4.75% as of the date of the filing of this Annual Report on Form 10-K.

The federal funds rate was raised in March,

May, June, July, September, November and December of 2022 and in February of 2023.

The rate of the increase in the federal funds rate

has declined, however, with the December 2022 increase coming in at 0.50% and the February 2023 rate increase of 0.25%, compared with

rate hikes at 0.75% each in June, July, September and November of 2022.

Looking to 2023, we anticipate a continued moderation of the inflation

rate when compared to the levels seen in 2022, as a result of these recent rate hikes, but expect that inflation will remain well above

the levels seen in the previous 10 years, when the annual inflation rate ranged from 0.1% to 2.4%.

If inflation is above the levels that

the Company anticipates, gross margins could be below plan and our business, operating results and cash flows may be adversely affected.

We pay close attention to the management of our working capital and operating expenses.

Some of our most significant operating expenses are labor costs, medical supplies and vehicle-related costs, such as fuel, maintenance, repair and insurance.

Insurance costs include premiums paid for coverage as well as reserves for estimated losses within the Company’s insurance policy deductibles.

We employ our proprietary technology to help drive improvements in productivity per transport and per shift.

We regularly analyze our workforce productivity to help achieve the optimum, cost-efficient labor mix for our locations.

This involves managing the mix of Company-employed labor and subcontracted labor as well as full-time and part-time employees.

The inflation rate in the United States, as measured by the Consumer Price Index, has generally trended up since early 2021.

This data is reported monthly, showing year-over-year changes in prices across a basket of goods and services.

Though the annual inflation rate declined to 4.1% for the full year 2023 from 8.0% in 2022, it remains above historical averages.

The increased inflation rate has had an impact on the Company’s expenses in several areas, including wages, fuel and medical and other supplies.

This has had the effect of compressing gross profit margins, as the Company is generally unable to pass these higher costs on to its customers, particularly in the short term.

In a continued attempt to dampen inflation, the U.S.

Federal Reserve implemented four interest rate hikes in 2023, raising its benchmark rate to the current level of 5.25-5.50% as of the date of this Annual Report.

Looking into 2024, we anticipate a continued moderation of the inflation rate as a result of these recent interest rate increases, with an annual rate similar to those witnessed in the 2010-2020 period, when the annual inflation rate ranged from 0.1% to 3.2%.

If inflation is above the levels that the Company anticipates, gross margins could be below plan and our business, operating results and cash flows may be adversely affected.

Trip Volumes and Average Trip Price

A “trip” is defined as an instance where the Company completes the transportation of a patient to a specific destination, for which we are able to charge a fee.

This metric does not include instances where a trip is ordered and subsequently either canceled (by the customer) or declined (by the Company).

As trip volume represents the most basic unit of transportation service provided by the Company, the Company believes it is a good measure of the level of demand for the Company’s Transportation Services and is used by management to monitor and manage the scale of the business.

The average trip price is calculated by dividing the aggregate revenue from the total number of trips by the total number of trips and is an important indicator of the effective rate at which the Company is being compensated for its provision of Transportation Services.

Revenues generated from programs under which the Company is paid a fixed hourly or daily rate for the use of a fully staffed and equipped ambulance do not factor in the trip counts or average trip prices mentioned above.

We expect these fixed rate, “leased hour” programs to continue to account for an increasing proportion of the Transportation Services segment’s revenues in the future.

Historically, we have pursued an acquisition strategy to obtain enhanced capabilities or licenses to offer Mobile Health Services or Transportation Services.

Future acquisitions may also include companies that may help drive revenue, profitability, cash flow and stockholder value.

During the year ended December 31, 2023, we completed three acquisitions for an aggregate purchase price of $34.2 million.

During the year ended December 31, 2022, we completed five acquisitions for a purchase price of $69.1 million.

During the year ended December 31, 2021, we completed one acquisition for a purchase price of $2.3 million.

Investing in R&D and Enhancing our Customer Experience

performance is dependent on the investments we make in research and development, including our ability to attract and retain highly skilled

research and development personnel.

We must continually develop and introduce innovative new software services, integrate with third-party products

and services, mobile applications and other new offerings.

If we fail to innovate and enhance our brand and our products, our market position

and revenue will likely be adversely affected.

Our performance is dependent on the investments we make in research and development (“R&D”), including our ability to attract and retain highly skilled R&D personnel.

We intend to develop and introduce innovative new software services, integrations with third-party products and services, mobile applications and other new offerings.

If we fail to innovate and enhance our brand and our products, our market position and revenue may be adversely affected.

Regulatory Environment

is subject to federal, state and local regulations including healthcare and emergency medical services laws and regulations and tax laws

and regulations.

The Company is subject to federal, state and local regulations, including healthcare and emergency medical services laws and regulations and tax laws and regulations.

The Company’s current business plan assumes no material change in these laws and regulations.

In the event any

such change occurs, compliance with new laws and regulations might significantly affect its operations and cost of doing business.

Components of Results

of Operations

business consists of two reportable segments — Transportation services and Mobile Health services.

The Company evaluates

the performance of both segments based primarily on results of its operations.

Accordingly, other income and expenses not included in

results from operations are only included in the discussion of consolidated results of operations.

Company’s revenue consists of services provided by its Transportation segment and its Mobile Health segment.

In the event that any such change occurs, compliance with new laws and regulations may significantly affect the Company’s operations and cost of doing business.

The spread of COVID-19 and the related shutdowns and restrictions had a mixed impact on the Company’s business.

In the ambulance transportation business, which predominantly comprises non-emergency medical transportation, the Company initially saw a decline in volumes from historical and expected levels, as elective surgeries and other procedures were postponed.

In some of the Company’s larger markets, such as New York and California, there were declines in trip volume.

In addition, the Company experienced lost revenues associated with sporting, concerts and other events, as those events were cancelled or significantly restricted (or entirely eliminated) the number of permitted attendees.

Ambulance transports and event-related revenues have both since recovered to pre-COVID levels or higher.

There were two areas in which the Company initially experienced positive business impacts from COVID-19.

In April and May 2020, the Company participated in an emergency project with FEMA in the New York City area.

This engagement resulted in incremental transportation revenue.

In addition, in response to the need for widespread COVID-19 testing, EMTs and paramedics, the Company formed a new subsidiary, Rapid Reliable Testing, LLC (“RRT”), with the goal of performing COVID-19 tests at nursing homes, municipal sites, businesses, schools and other venues.

RRT is part of the Mobile Health Services segment.

As COVID-19 testing activity slowed and accounted for a more minor portion of the Company’s revenues, RRT expanded its services beyond COVID-19 testing to a wide variety of tests, vaccinations and other procedures.

The Company estimates that during 2023, its revenue from COVID-19 related services accounted for less than 1% of total revenues, compared to about 17% in 2022 and nearly 35% in 2021.

The Company’s current business plan assumes increased demand for Mobile Health Services, a demand that was accelerated by the pandemic, but which is also being driven by longer-term factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s offices and hospitals.

Components of Results of Operations

Our business consists of three reportable segments — Mobile Health Services, Transportation Services and Corporate.

All revenue and cost of goods sold are contained within the Mobile Health Services and Transportation Services segments.

Accordingly, revenues and cost of goods sold are discussed below on a consolidated level and are also broken down between Mobile Health Services and Transportation Services.

Operating expenses are discussed on a consolidated level and broken down among all three segments.

The Company evaluates the performance of each of its segments based primarily on its results of operations.

Accordingly, other income and expenses not included in results of operations are only included in the discussion of consolidated results of operations.

The Company’s revenue consists of services provided by its Mobile Health Services segment and its Transportation Services segment.

Cost of Revenues

of revenues consists primarily of revenue generating wages paid to employees, vehicle insurance costs (including insurance premiums and

costs incurred under the insurance deductibles), maintenance, fuel, laboratory fees, facility rent, medical supplies and subcontractors.

We expect cost of revenue to continue to rise in proportion to the expected increase in revenue.

Cost of revenues consists primarily of revenue generating wages paid to employees, fees to paid to subcontractors, medical supplies, vehicle insurance costs (including insurance premiums and costs incurred under the insurance deductibles), maintenance, fuel and facility rent.

We expect cost of revenues to continue to rise as we grow our business.

Operating Expenses

General and Administrative Expenses

and administrative expenses consist primarily of salaries, bad debt expense, insurance expense, consultant fees, and professional fees

for accounting services.

We expect our general and administrative expense to increase as we scale up headcount with the growth of our

business, and as a result of operating as a public company, including compliance with SEC rules and regulations, audit, additional insurance

expenses, investor relations activities, and other administrative and professional services.

General and administrative expenses consist primarily of salaries, bad debt expense, insurance expense, consultant fees and professional fees for accounting services.

We expect our general and administrative expenses to increase as we continue to scale our business and grow headcount and as a result of operating as a public company, including our

compliance with SEC rules and regulations, audit activities, additional insurance expenses, investor relations activities and other administrative and professional services.

Depreciation and Amortization

depreciates its assets using the straight-line method over the estimated useful lives of the respective assets.

Amortization of intangibles

consists of amortization of definite-lived intangible assets over their respective useful lives.

Regulatory Expenses

and regulatory expenses include legal fees, consulting fees related to healthcare compliance, claims processing fees and legal settlements.

Technology and

development Expenses

Technology and development expense, net of capitalization, consists

primarily of costs incurred in the design and development of DocGo’s proprietary technology, third-party software and technologies.

We expect technology and development expense to increase in future periods to support our growth, including as we invest in the optimization,

accuracy and reliability of our platform to help drive efficiency in our operations.

These expenses may vary from period to period as

a percentage of revenue, depending primarily upon when we choose to make more significant investments, which is in turn, dependent on

numerous factors, including when we plan to enter into new business lines or customer sales channels.

Sales, Advertising and Marketing

sales and marketing expenses consist of costs directly associated with our sales and marketing activities, which primarily include sales

commissions, marketing programs, trade shows, and promotional materials.

We expect that our sales and marketing expenses will continue

to increase over time as we increase our marketing activities, grow our domestic and international operations, and continue to build brand

As the Company expands its sales efforts to include the direct-to-consumer channel, marketing expenses are likely to increase

as a percentage of revenues, given the marketing-intensive nature of that sales channel.

The Company depreciates its assets using the straight-line method over the estimated useful lives of the respective assets.

Amortization of intangibles consists of amortization of definite-lived intangible assets over their respective useful lives.

Legal and Regulatory Expenses

Legal and regulatory expenses include legal fees, consulting fees related to healthcare compliance and legal settlements.

Technology and Development Expenses

Technology and development expenses consists primarily of costs incurred in the design and development of the Company’s proprietary technology, third-party software and technologies.

We expect technology and development expenses to increase in future periods to support our growth, including our intent to continue investing in the optimization, accuracy and reliability of our dispatch and communication platform and drive efficiency in our operations.

These expenses may vary from period to period as a percentage of revenues, depending primarily upon when we choose to make more significant investments, particularly when entering new business lines or customer sales channels.

Sales, Advertising and Marketing Expenses

Our sales, advertising and marketing expenses consist of costs directly associated with our sales and marketing activities, which primarily include sales commissions, marketing programs, trade shows, promotional materials and general branding.

We expect our sales, advertising and marketing expenses to continue to increase over time as we increase our marketing activities, grow our domestic and international operations and continue to build brand awareness.

Interest Expense

expense consists primarily of interest on our outstanding borrowings under our outstanding notes payable, credit line and financing obligations.

Interest expense consists primarily of interest on our outstanding borrowings under our outstanding notes payable and financing obligations, including our Revolving Facility.

Results of Operations

Comparison of Fiscal

2022 with Fiscal 2021

Years Ended December 31,

Comparison of Fiscal 2023 with Fiscal 2022

Year Ended December 31, Change

$ in Millions 2023 2022

Actual Results % of Total Revenue Actual Results % of Total Revenue

Revenues, net $ 624.3 100.0 % $ 440.5 100.0 % $ 183.8 41.7 %

Cost of revenues 428.9 68.7 % 285.8 64.9 % 143.1 50.1 %

6 unchanged sentences

Total expenses 609.2 97.6 % 418.7 95.1 % 190.5 45.5 %

Income (loss) from operations

Other income (expenses):

Income from operations 15.1 2.4 % 21.8 4.9 % (6.7)

Other income:

Interest income (expense), net 1.7 0.3 % 0.8 0.2 % 0.9 112.5 %

Gain (loss) from Payroll Protection Program (“PPP”) loan forgiveness

Gain on remeasurement of warrant liabilities — — % 1.1 0.3 % (1.1)

Gain (loss) on equity method investment

Change in fair value of contingent liability 1.4 0.2 % — — % 1.4

(Loss) on equity method investments (0.3) (0.1) % — — % (0.3)

Gain on remeasurement of finance leases — — % 1.4 0.3 % (1.4)

Gain on bargain purchase — — % 1.6 0.4 % (1.6)

Loss on disposal of fixed assets (0.9) (0.1) % — — % (0.9)

Goodwill impairment — — % (2.9) (0.7) % 2.9

Other expense (0.7) (0.1) % (1.0) (0.2) % 0.3

Total other income 1.2 0.2 % 1.0 0.2 % 0.2 20.0 %

Net income before (provision for) benefit from income tax 16.3 2.6 % 22.8 5.2 % (6.5)

(Provision for) benefit from income taxes (6.2) (1.0) % 7.9 1.8 % (14.1)

Net income 10.0 1.6 % 30.7 7.0 % (20.7)

Net income (loss) attributable to noncontrolling interests 3.2 0.5 % (3.9) (0.9) % 7.1 182.1 %

Net income attributable to stockholders of DocGo Inc.

and Subsidiaries $ 6.9 1.1 % $ 34.6 7.9 % $ (27.7)

For the year ended December 31, 2023, total revenues were $624.3 million, an increase of $183.8 million, or 41.7%, from the total revenues recorded for the year ended December 31, 2022.

Mobile Health Services

For the year ended December 31, 2023, Mobile Health Services revenues were $442.8 million, an increase of $116.9 million, or 35.9%, as compared with the year ended December 31, 2022.

The increase in revenues was primarily due to an expansion in services offered by the Mobile Health Services segment, particularly in the government customer sector.

This expansion accelerated during the year ended December 31, 2023 as the Company extended several large customer contracts and introduced a broader range of services.

Transportation Services

For the year ended December 31, 2023, Transportation Services revenues were $181.5 million, an increase of $66.9 million, or 58.3%, as compared with the year ended December 31, 2022.

This increase was due to a 15.8% increase in trip volumes, from 216,009 trips for the year ended December 31, 2022 to 250,114 trips for the year ended December 31, 2023.

The increase in trip volumes was due to a combination of growth in the Company’s customer base in certain core markets and acquisitions made during the second half of 2022.

Our average trip price increased from $380 in the year ended December 31, 2022 to $407 in the year ended December 31, 2023.

The increase in the average trip price in 2023 reflected a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports resulting in higher prices per trip.

The average trip price also benefited from an 8.7% increase in the average Medicare reimbursement rate for ambulance transports.

The Medicare ambulance fee schedule has increased by a further 2.4%, effective January 1, 2024.

Cost of Revenues

For the year ended December 31, 2023, total cost of revenues (exclusive of depreciation and amortization) increased by 50.1% compared to the year ended December 31, 2022, while revenues increased by approximately 41.7%.

Cost of revenues as a percentage of revenues increased to 68.7% in the year ended December 31, 2023 from 64.9% in the year ended December 31, 2022.

Total cost of revenues in the year ended December 31, 2023 increased by $143.1 million compared to the same period in 2022.

This increase was primarily attributable to a $44.0 million increase in total compensation, due to higher headcount for both the Transportation Services and Mobile Health Services segments;

an $80.2 million increase in subcontracted labor costs, primarily driven by new projects in the Mobile Health Services segment that required a greater number of personnel and certain more highly specialized personnel than the Company was able to initially provide through its existing staff;

a $19.6 million increase in medical and related supplies;

a $2.1 million increase in travel costs for field personnel and other clinicians who traveled out of their home regions to provide Mobile Health Services;

and a $1.6 million net increase in other cost of revenues categories.

These items were partially offset by a $2.3 million decline in vehicle costs, as the Company exited certain rental agreements, and a $2.1 million reduction in lab fees, as COVID testing services declined to an immaterial amount in 2023.

For the Mobile Health Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2023 amounted to $306.2 million, up 53.7% from $199.2 million in the year ended December 31, 2022.

Cost of revenues as a percentage of revenues increased to 69.1% from 61.1% in the prior year period, despite a significant increase in revenues, reflecting higher compensation expenses as a result of headcount growth, significantly higher subcontracted labor costs and increased costs for medical supplies.

For the Transportation Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2023 amounted to $122.7 million, up 41.8% from $86.5 million in the year ended December 31, 2022.

Cost of revenues as a percentage of revenues decreased to 67.6% from 75.5% in the prior year, reflecting the impact of higher per-trip prices, increased revenues from standby contracts (for which we are paid a daily or hourly rate) and the overall increase in revenues, as well as a decline in the average fuel price.

Operating Expenses

For the year ended December 31, 2023, operating expenses were $180.3 million compared to $132.9 million for the year ended December 31, 2022, an increase of $47.4 million, or 35.7%.

As a percentage of revenues, operating expenses decreased from 30.2% in 2022 to 28.9% in 2023, even as the Company added to its management infrastructure and total compensation increased, due to the significant increase in overall revenues described above.

The increase of $47.4 million related primarily to a $27.1 million increase in total compensation, which included costs for both directly employed and subcontracted staff due to investments in and expansion of corporate infrastructure to support the revenue growth, as well as an increase in stock-based compensation expense;

a $5.7 million increase in depreciation and amortization due to an increase in assets to support revenue growth and capitalized software amortization, as well as recently acquired companies;

a $4.9 million increase in IT infrastructure, driven by the Company’s business and headcount expansion;

a $2.5 million increase in insurance costs, reflecting higher headcount, a larger vehicle fleet and expanded operations;

a $1.3 million increase in rent and utilities relating to the Company’s ongoing geographic expansion;

and a $5.9 million net increase across a variety of expense categories.

For the Mobile Health Services segment, operating expenses in the year ended December 31, 2023 were $56.3 million, up from $33.9 million in the year ended December 31, 2022.

Operating expenses as a percentage of revenues increased to 12.7% from 10.4% in 2022, despite the increase in Mobile Health Services revenues, reflecting significant expenditures that were made in 2023 related to the expansion of services and geographic areas of operation, as well as the continued buildout of the Mobile Health Services management infrastructure and the costs of developing the Company’s “on-demand” direct-to-consumer offering.

For the Transportation Services segment, operating expenses in the year ended December 31, 2023 were $55.2 million, compared to $43.0 million in the year ended December 31, 2022.

The increase in operating expenses for this segment, in absolute dollar terms, was driven primarily by higher compensation expense and depreciation charges, reflecting the expansion of the business, including recent acquisitions.

Operating expenses as a percentage of revenues decreased to 30.4% for the year ended December 31, 2023 from 37.5% in the year ended December 31, 2022.

For the Corporate segment, which represents primarily shared services that are not contained within the entities included in either the Mobile Health Services or Transportation Services segments, operating expenses in the year ended December 31, 2023 were $68.8 million, compared to $55.1 million in the year ended December 31, 2022.

The increase in operating expenses for this segment, in absolute dollar terms, was primarily driven by higher compensation expenses, reflecting the ongoing build-out of the Company’s corporate human resources infrastructure.

Corporate expenses amounted to approximately 11.0% of total consolidated revenues in 2023, compared to 12.5% in 2022, reflecting the significant increase in total consolidated revenues.

Interest Income, Net

For the year ended December 31, 2023, the Company recorded approximately $1.7 million of interest income, net compared to $0.8 million of interest income, net in the year ended December 31, 2022.

This increase was primarily due to higher rates of interest earned on balances in the Company's interest-bearing accounts in the year ended December 31, 2023, which reflected significantly higher market interest rates.

The higher rates of interest earned outweighed the impact of the lower average cash balances in 2023.

Gain on Remeasurement of Warrant Liabilities

During the year ended December 31, 2023, there were no gains or losses recorded relating to remeasurement of warrant liabilities, as all warrants were redeemed during the third quarter of 2022.

During the year ended December 31, 2022, the Company recorded a gain of approximately $1.1 million from the remeasurement of warrant liabilities.

The warrants were marked-to-market in each reporting period, and this gain reflected the decline in the Company’s stock price relative to the beginning of the period.

Change in Fair Value of Contingent Liability

During the year ended December 31, 2023, the Company recorded a change in fair value of contingent liability of approximately $1.4 million, reflecting a decline in the anticipated payments to be made for a recent acquisition, based upon

performance compared to certain targets.

There was no related change in fair value recorded in the year ended December 31, 2022.

(Loss) Gain on Equity Method Investments

During the year ended December 31, 2023, the Company recorded a loss on equity method investments of approximately $0.3 million representing its share of the losses incurred by an entity in which the Company has a minority interest.

During the year ended December 31, 2022, the Company recorded a gain on equity method investments of $8,919.

Gain on Remeasurement of Finance Leases

During the year ended December 31, 2023, there were no gains or losses recorded relating to remeasurement of finance leases.

During the year ended December 31, 2022, the Company recorded a gain on remeasurement of finance leases of $1.4 million.

Gain on Bargain Purchase

Other income (loss)

Total other income (expense)

Net income (loss) before income tax benefit (expense)

Benefit (provision) for income tax

Net income (loss)

During the year ended December 31, 2023, the Company recorded no gain or loss on bargain purchase.

During the year ended December 31, 2022, the Company recorded a gain on bargain purchase of $1.6 million.

Loss on Disposal of Fixed Assets

During the year ended December 31, 2023, the Company recorded a loss on disposal of fixed assets of $0.9 million, compared to a loss on disposal of fixed assets of $21,000 during the year ended December 31, 2022.

Goodwill Impairment

During the year ended December 31, 2023, the Company did not record any impairment to goodwill.

During the year ended December 31, 2022, the Company recorded a goodwill impairment of $2.9 million, relating to the Company’s exit from the medical transportation market in California.

(Provision for) Benefit from Income Taxes

During the year ended December 31, 2023, the Company recorded a provision for income taxes of $6.2 million compared to an income tax benefit of $7.9 million in the year ended December 31, 2022.

The tax benefit in 2022 was due to the release of the valuation allowance recorded in previous years for net operating losses, as the Company determined that it was more likely than not that it would be able to realize its net operating loss carryforwards in the future.

Net Income (Loss) Attributable to Noncontrolling Interests

For the year ended December 31, 2023, the Company had net income attributable to noncontrolling interests of approximately $3.2 million compared to a net loss attributable to noncontrolling interests of $3.9 million for the year ended December 31, 2022.

The income compared to the prior year period loss reflected improved performance in the Company’s joint venture markets in the year ended December 31, 2023.

Comparison of Fiscal 2022 with Fiscal 2021

Year Ended December 31, Change

$ in Millions 2022 2021

Actual Results % of Total Revenue Actual Results % of Total Revenue

Revenues, net $ 440.5 100.0 % $ 318.7 100.0 % $ 121.8 38.2 %

Cost of revenues 285.8 64.9 % 209.0 65.6 % $ 76.8 36.8 %

Operating expenses:

General and administrative 103.4 23.5 % 74.9 23.5 % $ 28.5 38.1 %

Depreciation and amortization 10.6 2.4 % 7.5 2.4 % $ 3.1 40.7 %

Legal and regulatory 8.8 2.0 % 3.9 1.2 % $ 4.9 125.6 %

Technology and development 5.4 1.2 % 3.3 1.0 % $ 2.1 63.6 %

Sales, advertising and marketing 4.7 1.1 % 4.8 1.5 % $ (0.1) (2.4 %)

Total expenses 418.7 95.1 % 303.4 95.2 % $ 115.3 38.0 %

Income from operations 21.8 4.9 % 15.4 4.8 % $ 6.5

Other income:

Interest income (expense), net 0.8 0.2 % (0.8) (0.2) % $ 1.6 200.0 %

Gain on remeasurement of warrant liabilities 1.1 0.3 % 5.2 1.6 % $ (4.1)

Change in fair value of contingent liability — — % — — % $ —

(Loss) on equity method investments — — % (0.1) — % $ 0.1

Gain on remeasurement of finance leases 1.4 0.3 % — — % $ 1.4

Gain on bargain purchase 1.6 0.4 % — — % $ 1.6

Gain from PPP loan forgiveness — — % 0.1 — % $ (0.1)

(Loss) on disposal of fixed assets — — % — — % $ —

Goodwill impairment (2.9) (0.7) % — — % $ (2.9)

Other expense (1.0) (0.2) % — — % $ (1.0)

Total other income 1.0 0.2 % 4.4 1.4 % $ (3.4) (77.3 %)

Net income before benefit from (provision for) income tax 22.8 5.2 % 19.8 6.2 % $ 3.0

Benefit from (provision for) income tax 7.9 1.8 % (0.6) (0.2) % $ 8.5

Net income 30.7 7.0 % 19.2 6.0 % $ 11.5

Net (loss) attributable to noncontrolling interests (3.9) (0.9) % (4.5) (1.4) % $ 0.6 13.3 %

Net income attributable to stockholders of DocGo Inc.

and Subsidiaries $ 34.6 7.9 % $ 23.7 7.4 % $ 10.9

For the year ended December

31, 2022, total revenues were $440.5 million, an increase of $121.8 million, or 38%, from the total revenues recorded in the year ended

December 31, 2021.

Mobile Health

For the year ended December 31, 2022, Mobile Health revenue was $325.9

million, an increase of $91.4 million, or 39%, as compared with the year ended December 31, 2021.

This increase was primarily due to the

expansion of the services offered by this segment, particularly with respect to testing, vaccination and other healthcare services revenues.

This expansion accelerated through 2021 and into 2022 as the Company increased its customer base, primarily in the municipal customer

segment, and its geographic reach, while extending the terms of and/or expanding the scope of several large customer contracts and introducing

a broader range of services.

Compared to the prior year, 2022 featured significantly lower COVID-19 testing revenue, which was outweighed

by the substantial increase in other Mobile Health services, as the Mobile Health segment transitioned away from its dependence on COVID-19

related revenue.

COVID-19 testing continued to be a significant driver of Mobile Health revenues in the first half of 2022, but dropped

sharply in the third quarter of the year, and represented an insignificant proportion of total revenues in the fourth quarter.

For the year ended December 31, 2022, total revenues were $440.5 million, an increase of $121.8 million, or 38%, from the total revenues recorded in the year ended December 31, 2021.

Mobile Health Services

For the year ended December 31, 2022, Mobile Health Services revenues were $325.9 million, an increase of $91.4 million, or 39%, as compared with the year ended December 31, 2021.

This increase was primarily due to the expansion of the services offered by this segment, particularly with respect to testing, vaccination and other healthcare services revenues.

This expansion accelerated through 2021 and into 2022 as the Company increased its customer base, primarily in the municipal customer segment, and its geographic reach, while extending the terms of and/or expanding the scope of several large customer contracts and introducing a broader range of services.

Compared to the prior year, 2022 featured significantly lower COVID-19 testing revenue, which was outweighed by the substantial increase in other Mobile Health Services, as the Mobile Health Services segment transitioned away from its dependence on COVID-19 related revenue.

COVID-19 testing continued to be a significant driver of Mobile Health Services revenues in the first half of 2022, but dropped sharply in the third quarter of the year, and represented an insignificant proportion of total revenues in the fourth quarter.

Transportation Services

For the year ended December 31, 2022, Transportation Services revenue

was $114.6 million an increase of $30.3 million, or 36%, as compared with the year ended December 31, 2021.

This increase was due to a

20% increase in transportation trip volumes, from 180,753 trips for the year ended December 31, 2021 to 216,009 trips for the year ended

December 31, 2022.

The increase in trip volumes was due to a combination of growth in the customer base in certain core markets, entry

into new markets in 2021 and early 2022 and acquisitions made during the second half of 2022.

Our average trip price increased from $301

in the year ended December 31, 2021, to $380 in the year ended December 31, 2022.

The increase in the average trip price in 2022 reflected

a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity

transports resulting in higher prices per trip.

The average trip price also benefited from a 5.1% increase in the average Medicare reimbursement

rate for ambulance transports.

In October 2022, the Centers for Medicare and Medicaid Services (CMS) announced that the Medicare ambulance

fee schedule would be increasing by a further 8.7%, effective January 1, 2023.

Cost of Revenue

For the year ended December 31, 2022, total cost of revenue (exclusive

of depreciation and amortization) increased by 37%, as compared to the year ended December 31, 2021, while revenue increased by approximately

Cost of revenue as a percentage of revenue decreased to 64.9% in 2022 from 65.5% in 2021.

In absolute dollar terms,

cost of revenue in the year ended December 31, 2022 increased by $76.8 million from the levels of the year ended December 31, 2021.

was primarily attributable to a $64.9 million increase in total compensation, due to higher headcount for both the Transportation Services

and Mobile Health segments;

a $16.0 million increase in subcontracted labor, driven mostly by the Mobile Health segment, where the Company

did not have sufficient personnel to staff the initial phases of large new projects;

$13.6 million increase in vehicle costs, driven by

a continued increase in the Company’s vehicle fleet and higher fuel and maintenance costs, as well as costs incurred to rent vehicles

to provide Mobile Health services;

a $2.1 million increase in travel costs, due to field personnel and other clinicians who traveled out

of their home regions to provide Mobile Health services;

For the year ended December 31, 2022, Transportation Services revenues were $114.6 million, an increase of $30.3 million, or 36%, as compared with the year ended December 31, 2021.

This increase was due to a 20% increase in trip volumes, from 180,753 trips for the year ended December 31, 2021 to 216,009 trips for the year ended December 31, 2022.

The increase in trip volumes was due to a combination of growth in the customer base in certain core markets, entry into new markets in 2021 and early 2022 and acquisitions made during the second half of 2022.

Our average trip price increased from $301 in the year ended December 31, 2021 to $380 in the year ended December 31, 2022.

The increase in the average trip price in 2022 reflected a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports resulting in higher prices per trip.

The average trip price also benefited from a 5.1% increase in the average Medicare reimbursement rate for ambulance transports.

Cost of Revenues

For the year ended December 31, 2022, total cost of revenues (exclusive of depreciation and amortization) increased by 37%, as compared to the year ended December 31, 2021, while revenues increased by approximately 38%.

Cost of revenues as a percentage of revenues decreased to 64.9% in 2022 from 65.5% in 2021.

In absolute dollar terms, cost of revenues in the year ended December 31, 2022 increased by $76.8 million from the levels of the year ended December 31, 2021.

This was primarily attributable to a $64.9 million increase in total compensation, due to higher headcount for both the Transportation Services and Mobile Health Services segments;

a $16.0 million increase in subcontracted labor, driven mostly by the Mobile Health Services segment, where the Company did not have sufficient personnel to staff the initial phases of large new projects;

$13.6 million increase in vehicle costs, driven by a continued increase in the Company’s vehicle fleet and higher fuel and maintenance costs, as well as costs incurred to rent vehicles to provide Mobile Health Services;

a $2.1 million increase in travel costs, due to field personnel and other clinicians who traveled out of their home regions to provide Mobile Health Services;

a $0.4 million increase in facilities and related costs;

and approximately $2.6

million in increases across a variety of other cost of revenue categories relating to the Company’s increased scale and geographic

These items were partially offset by a $21.1 million decrease in lab fees related to COVID-19 testing activity, reflecting sharply

lower COVID-19 testing activity in the second half of 2022, lower per-test lab fees and a shift toward rapid tests;

and a $1.8 million

decline in medical supplies, reflecting a decline in COVID-19 testing activity and improved sourcing of various supplies.

For the Mobile Health segment,

cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 amounted to $199.2 million, compared

to $145.2 million in the year ended December 31, 2021.

Cost of revenues as a percentage of revenues decreased slightly to 61.1% from 61.9%,

due to the increase in revenues and the continued shift away from higher-cost subcontracted labor toward Company personnel during 2022,

which was partially offset by higher compensation costs associated with some of the Company’s newer projects.

For the Transportation services

segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 was $86.5 million, an increase

of $23.1 million, or 36%, from the year ended December 31, 2021.

Cost of revenues as a percentage of revenues were essentially unchanged,

at 75.5% in 2022 compared to 75.3% in 2021.

Increased volumes and higher average trip prices, as described above, combined with lower

average hourly wages, as recent market wage pressures began to subside, and as the Company more effectively managed its staff to reduce

overtime hours for field employees, to offset the effects of increased fuel costs.

Fuel prices moderated somewhat during the third quarter

and in the fourth quarters of 2022, but the full-year average fuel price for 2022 was approximately 29% above the full-year average for

We anticipate that fuel prices will remain at elevated levels for 2023, but we expect that the full-year average for 2023 will be

lower than it was in 2022.

and approximately $2.6 million in increases across a variety of other cost of revenues categories relating to the Company’s increased scale and geographic presence.

These items were partially offset by a $21.1 million decrease in lab fees related to COVID-19 testing activity, reflecting sharply lower COVID-19 testing activity in the second half of 2022, lower per-test lab fees and a shift toward rapid tests;

and a $1.8 million decline in medical supplies, reflecting a decline in COVID-19 testing activity and improved sourcing of various supplies.

For the Mobile Health Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 amounted to $199.2 million, compared to $145.2 million in the year ended December 31, 2021.

Cost of revenues as a percentage of revenues decreased slightly to 61.1% from 61.9%, due to the increase in revenues and

the continued shift away from higher-cost subcontracted labor toward Company personnel during 2022, which was partially offset by higher compensation costs associated with some of the Company’s newer projects.

For the Transportation Services segment, cost of revenues (exclusive of depreciation and amortization) in the year ended December 31, 2022 was $86.5 million, an increase of $23.1 million, or 36%, from the year ended December 31, 2021.

Cost of revenues as a percentage of revenues were essentially unchanged, at 75.5% in 2022 compared to 75.3% in 2021.

Increased volumes and higher average trip prices, as described above, combined with lower average hourly wages, as recent market wage pressures began to subside and the Company more effectively managed its staff to reduce overtime hours for field employees, to offset the effects of increased fuel costs.

Fuel prices moderated somewhat during the third quarter and in the fourth quarters of 2022, but the full-year average fuel price for 2022 was approximately 29% above the full-year average for 2021.

We anticipated that fuel prices would remain at elevated levels for 2023, but we expected that the full-year average for 2023 would be lower than it was in 2022.

Operating Expenses

For the year ended December 31, 2022, operating expenses were $132.9

million compared to $94.4 million for the year ended December 31, 2021, an increase of 41%.

As a percentage of revenue, operating expenses

increased slightly, from 29.6% in 2021 to 30.2% in 2022, despite the significant increase in overall revenues described above, as the

Company continued to add to its management infrastructure and incurred a full year’s worth of expenses relating to its status as

a public company.

The increase of $38.3 million related primarily to a $20.1 million increase in total compensation, which includes salaries,

benefits, bonuses and commissions for both direct and subcontracted labor, reflecting higher headcount driven by the Company’s overall

growth and expansion;

a $7.1 million increase in legal, accounting and other professional fees related to increased revenue and related

contract generation and SEC filing-related costs;

a $2.8 million increase in insurance costs reflecting the growth and expansion of the

Company, as well as the addition of directors and officers (D&O) insurance in 2022;

a $3.2 million increase in depreciation and amortization

charges due to an increase in assets to support revenue growth and capitalized software amortization, including from recently acquired

For the year ended December 31, 2022, operating expenses were $132.9 million compared to $94.4 million for the year ended December 31, 2021, an increase of 41%.

As a percentage of revenues, operating expenses increased slightly, from 29.6% in 2021 to 30.2% in 2022, despite the significant increase in overall revenues described above, as the Company continued to add to its management infrastructure and incurred a full year’s worth of expenses relating to its status as a public company.

The increase of $38.3 million related primarily to a $20.1 million increase in total compensation, which includes salaries, benefits, bonuses and commissions for both direct and subcontracted labor, reflecting higher headcount driven by the Company’s overall growth and expansion;

a $7.1 million increase in legal, accounting and other professional fees related to increased revenues and related contract generation and SEC filing-related costs;

a $2.8 million increase in insurance costs reflecting the growth and expansion of the Company, as well as the addition of directors and officers (D&O) insurance in 2022;

a $3.2 million increase in depreciation and amortization charges due to an increase in assets to support revenue growth and capitalized software amortization, including from recently acquired companies;

a $2.3 million increase in rent utility expenses due to the Company’s ongoing growth and geographic expansion;

million increase in IT infrastructure, driven by the Company’s business and headcount expansion;

and a $0.6 million increase in

marketing expenses, driven in part by expenditures made to develop and expand the Company’s direct-to-consumer (DTC) and other Mobile

Health programs.

These items were partially offset by a $0.7 million decline witnessed across several operating expense categories, such

as travel, commissions and general office expenses.

The Company anticipates that operating expenses will continue to increase along with

the Company’s revenue growth and remain in the range of 25%-30% of revenue in the coming quarters.

For the Mobile Health segment,

operating expenses in the year ended December 31, 2022 were $58.0 million, up 25% from operating expenses of $46.3 million in the year

ended December 31, 2021.

Operating expenses as a percentage of revenues decreased to 17.8% from 19.8% in 2021, due to the increase in

Mobile Health revenues, which outweighed the effect of the significant expenditures that were made in 2022 in the expansion of services

and geographic areas of operation, as well as the continued buildout of the Mobile Health management infrastructure and the costs of developing

the Company’s “on-demand” direct-to-consumer offering.

For the Transportation services

segment, operating expenses in the year ended December 31, 2022 were $74.0 million, up $26.6 million, or 56%, from the year ended December

Operating expenses as a percentage of revenues increased to 64.6% from 56.3% in the prior year period, despite the increase

in revenues, primarily due to increases in the Company’s corporate overhead expenditures, as described above, as these expenses

were allocated to the Transportation segment for purposes of segment reporting.

Operating expenses for the Transportation segment were

also driven higher by the inclusion of the acquisitions the Company made in the second half of 2022.

a $2.9 million increase in IT infrastructure, driven by the Company’s business and headcount expansion;

and a $0.6 million increase in marketing expenses, driven in part by expenditures made to develop and expand the Company’s direct-to-consumer offering and other Mobile Health Services.

These items were partially offset by a $0.7 million decline witnessed across several operating expense categories, such as travel, commissions and general office expenses.

For the Mobile Health Services segment, operating expenses in the year ended December 31, 2022 were $58.0 million, up 25% from operating expenses of $46.3 million in the year ended December 31, 2021.

Operating expenses as a percentage of revenues decreased to 17.8% from 19.8% in 2021, due to the increase in Mobile Health Services revenues, which outweighed the effect of the significant expenditures that were made in 2022 in the expansion of services and geographic areas of operation, as well as the continued buildout of the Mobile Health Services management infrastructure and the costs of developing the Company’s “on-demand” direct-to-consumer offering.

For the Transportation Services segment, operating expenses in the year ended December 31, 2022 were $74.0 million, up $26.6 million, or 56%, from the year ended December 31, 2021.

Operating expenses as a percentage of revenues increased to 64.6% from 56.3% in 2021, despite the increase in revenues, primarily due to increases in the Company’s corporate overhead expenditures, as described above, as these expenses were allocated to the Transportation Services segment for purposes of segment reporting.

Operating expenses for the Transportation Services segment were also driven higher by the inclusion of the acquisitions the Company made in the second half of 2022.

Interest Income (Expense), Net

For the year ended December

31, 2022, the Company recorded $0.8 million of net interest income compared to $0.8 million of interest expense in the year ended December

This was due to a significantly higher amount of interest earned during 2022, resulting from an increase in the Company’s

cash balances in income-bearing accounts, coupled with higher rates of interest earned on balances in these accounts, which reflected

significantly higher market interest rates.

Gain/(loss) on Remeasurement of Warrant Liabilities

During the year ended December

31, 2022, the Company recorded a net gain of approximately $1.1 million from the remeasurement of warrant liabilities.

The warrants are

marked-to-market in each reporting period, and this gain reflected the decrease in DocGo’s stock price relative to the beginning

of the period.

During the year ended December 31, 2021, the Company recorded a net gain of $5.2 million on the remeasurement of warrant

On August 15, 2022, the Company announced the redemption of all of its outstanding warrants under the Warrant Agreement,

dated as of October 14, 2020, by and between Motion and Continental Stock Transfer & Trust Company, as warrant agent, on the redemption

date of September 16, 2022 (the “Redemption Date”).

Warrants surrendered for exercise on a cashless basis resulted in the

issuance of 1,406,371 shares.

For the year ended December 31, 2022, the Company recorded $0.8 million of interest income, net compared to $0.8 million of interest expense, net in the year ended December 31, 2021.

This was due to a significantly higher amount of interest earned during 2022, resulting from an increase in the Company’s cash balances in income-bearing accounts, coupled with higher rates of interest earned on balances in these accounts, which reflected significantly higher market interest rates.

Gain on Remeasurement of Warrant Liabilities

During the year ended December 31, 2022, the Company recorded a net gain of approximately $1.1 million from the remeasurement of warrant liabilities.

The warrants were marked-to-market in each reporting period, and this gain

reflected the decrease in DocGo’s stock price relative to the beginning of the period.

During the year ended December 31, 2021, the Company recorded a net gain of $5.2 million on the remeasurement of warrant liabilities.

On August 15, 2022, the Company announced the redemption of all of its outstanding warrants under the Warrant Agreement, dated as of October 14, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, on the redemption date of September 16, 2022 (the “Redemption Date”).

Warrants surrendered for exercise on a cashless basis resulted in the issuance of 1,406,371 shares of Common Stock.

A total of 68,514 warrants were not surrendered on the Redemption Date and were redeemed for $0.10 per warrant.

Gain/(Loss) on Equity Method Investment

During the year ended December

31, 2022, the Company recorded a gain on equity method investment of $8,919, representing its share of the losses incurred by an entity

in which the Company has a minority interest, which is accounted for under the equity method.

This investment was made in the fourth quarter

of 2021, during which period a loss of $66,818 was recorded in relation to this equity method investment.

Gain on Equity Method Investments

During the year ended December 31, 2022, the Company recorded a gain on equity method investments of $8,919, representing its share of the losses incurred by an entity in which the Company has a minority interest, which is accounted for under the equity method.

This investment was made in the fourth quarter of 2021, during which period a loss of $66,818 was recorded in relation to this equity method investment.

Gain on Bargain Purchase

During the year ended December

31, 2022, the Company recorded a gain on bargain purchase of approximately $1.6 million in relation to an acquisition made during the

fourth quarter of the year, wherein the tangible net asset value of the acquired entity exceeded the purchase price.

No such gain or loss

was recorded during the same period in 2021.

Gain/(Loss) from Remeasurement of Finance Leases

During the year ended December

31, 2022, the Company recorded a gain from remeasurement of finance leases of approximately $1.4 million, resulting from a change in estimated

remaining liabilities under the terms of its leases.

During the year ended December 31, 2022, the Company recorded a gain on bargain purchase of approximately $1.6 million in relation to an acquisition made during the fourth quarter of the year, wherein the tangible net asset value of the acquired entity exceeded the purchase price.

No such gain or loss was recorded during the same period in 2021.

Gain on Remeasurement of Finance Leases

During the year ended December 31, 2022, the Company recorded a gain on remeasurement of finance leases of approximately $1.4 million, resulting from a change in estimated remaining liabilities under the terms of its leases.

No such gain or loss was recorded in the same period in 2021.

Gain from PPP Loan Forgiveness

In 2021, the Company recorded

a $0.1 million gain due to the forgiveness of a loan that one of its subsidiaries had obtained via the government’s Paycheck Protection

Program (PPP) in 2020.

In 2021, the Company recorded a $0.1 million gain due to the forgiveness of a loan that one of its subsidiaries had obtained via the government’s Paycheck Protection Program (“PPP”) in 2020.

No gain from loan forgiveness was recorded during the year ended December 31, 2022.

Income Tax Benefit (Expense)

During the year ended December

31, 2022, the Company recorded an income tax benefit of $7.9 million compared to an income tax expense of $0.6 million in the year ended

December 31, 2021.

The tax benefit in 2022 was due to the release of the valuation allowance recorded in previous years for net operating

losses (NOLs), as the Company determined that it was now more likely than not that it would be able to realize its NOL carryforwards in

Net Loss Attributable to Noncontrolling Interest

For the year ended December

31, 2022, the Company had a net loss attributable to noncontrolling interest of approximately $3.8 million compared to a net loss attributable

to noncontrolling interest of $4.6 million for the year ended December 31, 2021.

For both periods, the loss reflected ongoing investments

in new markets that were entered into during 2021 and 2022, partially offset by income generated by those markets.

Benefit From (Provision For) Income Taxes

During the year ended December 31, 2022, the Company recorded a benefit from income taxes of $7.9 million compared to a provision for income taxes of $0.6 million in the year ended December 31, 2021.

Net Loss Attributable to Noncontrolling Interests

For the year ended December 31, 2022, the Company had a net loss attributable to noncontrolling interests of approximately $3.8 million compared to a net loss attributable to noncontrolling interests of $4.6 million for the year ended December 31, 2021.

For both periods, the loss reflected ongoing investments in new markets that were entered into during 2021 and 2022, partially offset by income generated by those markets.

Liquidity and Capital Resources

Since inception, DocGo has

completed three equity financing transactions as its principal source of liquidity.

Generally, the Company has utilized equity raised

to finance operations, investments in assets, ambulance operating licenses and to fund accounts receivable.

The Company has also funded

these activities through operating cash flows.

In November 2021, upon the completion of the merger between Motion and Ambulnz, the Company

received proceeds of approximately $158.1 million, net of transaction expenses.

Despite the fact that the Company generated positive net

income in the year ended December 31, 2022, operating cash flows are not always sufficient to meet immediate obligations arising from

current operations.

For example, as the business has grown, the Company’s expenditures for human capital and supplies has expanded

accordingly, and the timing of the payments for payroll and to associated vendors, compared to the timing of receipts of cash from customers,

frequently results in the need to use existing cash balances to fund these working capital needs.

The Company’s working capital

needs depend on many factors, including the overall growth of the Company and the various payment terms that are negotiated with customers

Future capital requirements depend on many factors, including potential acquisitions, DocGo’s level of investment in

technology and ongoing technology development, and rate of growth in existing markets and into new markets.

Capital requirements might

also be affected by factors outside of the Company’s control, such as interest rates, rising inflation and other monetary and fiscal

policy changes to the manner in which the Company currently operates.

Additionally, as the impact of the COVID-19 on the economy and on

the Company’s market environment and operations evolves, the Company routinely assesses its liquidity needs.

If the Company’s

growth rate is higher than is currently anticipated, resulting in greater-than-anticipated capital requirements, the Company might need

to, or choose to, raise additional capital through debt or equity financings.

On November 1, 2022, the Company

entered into a revolving loan and security agreement with two banks, with one bank acting as the administrative agent (the “Lenders”),

with an initial maximum commitment amount of $90,000,000.

The revolving facility includes the ability for the Company to request an increase

to the commitment by an additional amount of up to $50,000,000, though no Lender (nor the Lenders collectively) are obligated to increase

their respective commitments.

Borrowings under the revolving facility bear interest at a per annum rate equal to (i) at the Company’s

option, the (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin.

The applicable margins are based on

the Company’s consolidated net leverage ratio, adjusted on a quarterly basis.

The initial applicable margins are 1.25% for an adjusted

term SOFR loan and 0.25% for a base rate loan and will be updated based on the Company’s consolidated net leverage ratio.

The revolving

facility matures on November 1, 2027.

The revolving facility is secured by a first-priority lien on substantially all of the Company’s

present and future personal assets and intangible assets.

The revolving facility is subject to certain financial covenants, such as a

net leverage ratio and interest coverage ratio, as defined in the agreement.

As of the date of the filing of this Annual Report on Form

10-K, the Company has not made any draws under the facility and there are no amounts outstanding.

Considering the foregoing,

DocGo anticipates that its existing balances of cash and cash equivalents, future expected cash flows generated from its operations and

its available line of credit under the revolving facility (as further discussed in Note 9, “Line of Credit” to the Consolidated

Financial Statements) will be sufficient to satisfy operating requirements for at least the next twelve months.

Between the inception of DocGo’s wholly owned subsidiary Ambulnz and the Business Combination, Ambulnz completed three equity financing transactions as its principal source of liquidity.

In November 2021, upon the completion of the Business Combination and the PIPE Financing, the Company received proceeds of approximately $158.1 million, net of transaction expenses.

Generally, the Company has utilized proceeds from the equity financing transactions and the Business Combination to finance operations, invest in assets, make acquisitions and fund accounts receivable.

The Company has also funded these activities through operating cash flows.

Despite the fact that the Company generated positive net income for the year ended December 31, 2023, operating cash flows are not always sufficient to meet immediate obligations arising from current operations.

For example, as the business has grown, the Company’s expenditures for human capital and supplies has expanded accordingly, and the timing of the payments for payroll and to associated vendors, compared to the timing of receipts of cash from customers, frequently results in the need to use existing

cash balances to fund working capital needs.

During the year ended December 31, 2023, as a greater proportion of the Company’s overall revenues were generated through services provided to municipal customers with long payment cycles, and expenditures made by the Company to allow for the provision of these services were substantial, operating cash flows were not sufficient to meet these demands for working capital, leading to a marked decline in the Company’s cash balances.

As these invoices are collected, the Company expects cash flows to be sufficient for near term working capital needs.

The Company’s future working capital needs depend on many factors, including the overall growth of the Company and the various payment terms that are negotiated with customers and vendors.

The Company’s future capital requirements depend on many factors, including potential acquisitions, the Company’s level of investment in technology and ongoing technology development, and rate of growth in existing markets and into new markets.

Capital requirements might also be affected by factors outside of the Company’s control, such as interest rates, rising inflation and other monetary and fiscal policy changes to the manner in which the Company currently operates.

If the Company’s growth rate is higher than is currently anticipated, resulting in greater-than-anticipated capital requirements, the Company might need to, or choose to, raise additional capital through debt or equity financings.

This last factor was evident during the second half of 2023, leading to a draw down in the Company’s credit line during the fourth quarter of 2023 and the first quarter of 2024, as described below.

On November 1, 2022, the Company entered into the Credit Agreement, which provides for the Revolving Facility in the initial aggregate principal amount of $90 million.

The Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to $50 million, though no lender (nor the lenders collectively) is obligated to increase its respective commitments.

Borrowings under the Revolving Facility bear interest at a per annum rate equal to (i) at the Company’s option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin.

The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis.

The initial applicable margins were 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and are updated based on the Company’s consolidated net leverage ratio.

The Revolving Facility matures on November 1, 2027 and is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets.

The Revolving Facility is subject to certain financial covenants, such as a net leverage ratio and interest coverage ratio, as defined in the Credit Agreement.

On October 19, 2023, the Company drew down $25 million under the Revolving Facility, which amount remained outstanding as of December 31, 2023.

In February 2024, the Company repaid all amounts outstanding under the Revolving Facility, and no amounts are outstanding as of the date of this Annual Report.

Considering the foregoing, DocGo anticipates that its existing balances of cash and cash equivalents, future expected cash flows generated from its operations and its available line of credit under the Revolving Facility will be sufficient to satisfy operating requirements for at least the next twelve months.

Looking beyond the next twelve months, DocGo anticipates that expected future cash flows, its available line of credit and proceeds from potential additional financings will be sufficient to satisfy any operating and potential investing requirements.

Capital Resources

Comparison as of December 31, 2022 and December

As of December 31,

Working capital as of December 31, 2023 and December 31, 2022 was as follows:

December 31, Change

$ in Millions 2023 2022

3 unchanged sentences

Total working capital $ 168.8 $ 170.9 $ (2.2) (1.2 %)

As of December 31, 2022, available

cash totaled $157.3 million, which represented a decrease of $18.2 million compared to December 31, 2021, as changes to working capital

accounts and cash used for acquisitions in 2022 outweighed the positive cash flow generated by operations.

As of December 31, 2022, working

capital amounted to $170.9 million, which represented a decrease of $27.2 million compared to December 31, 2021, which reflected the decreased

cash balance in 2022.

Increased accounts receivable, which reflected the growth of the business and a shift towards higher credit quality

customers, who have longer payment terms, in 2022, were outweighed by the increase in current liabilities, which reflected the growth

of the business and amounts due to seller resulting from acquisitions.

Year ended December 31, 2022 and 2021

As of December 31,

As of December 31, 2023, available cash totaled $59.3 million, which represented a decrease of $98.0 million compared to December 31, 2022, reflecting a significant increase in accounts receivable and acquisitions made during the year ended December 31, 2023.

As of December 31, 2023, working capital amounted to $168.8 million, which represented a decrease of $2.2 million compared to December 31, 2022, which reflected the decreased cash balance in 2023.

Increased accounts receivable, which reflected the growth of the business and a shift towards higher credit quality customers who have longer payment cycles in 2023, were outweighed by the increase in current liabilities, which reflected the growth of

the business and amounts due to seller and contingent consideration resulting from acquisitions, as well as the draw down of $25 million under the terms of the Revolving Credit Facility.

Cash flows as of the years ended December 31, 2023 and 2022 were as follows:

December 31, Change

$ in Millions 2023 2022

Cash flow summary

Net cash provided by/(used in) operating activities

Net cash provided by/(used in) investing activities

Net cash (used in) provided by operating activities $ (64.2) $ 28.9 $ (93.1) (322.1 %)

Net cash used in investing activities (29.9) (38.4) 8.5 (22.1 %)

Net cash provided by (used in) financing activities 1.1 (6.2) 7.3 (117.7 %)

Effect of exchange rate changes 1.1 0.7 0.4 57.1 %

Net decrease in cash $ (91.9) $ (15.0) $ (76.9) 512.7 %

Cash flows as of the years ended December 31, 2022 and 2021 were as follows:

December 31, Change

$ in Millions 2022 2021

Cash flow summary

Net cash provided by (used in) operating activities $ 28.9 $ (1.9) $ 30.8 1621.1 %

Net cash used in investing activities (38.4) (8.6) (29.9) (347.7 %)

Net cash (used in) provided by financing activities (6.2) 155.2 (161.4) (104.0 %)

Effect of exchange rate changes 0.7 — 0.7 100.0 %

Net (decrease) increase in cash $ (15.0) $ 144.7 $ (159.7) (110.4 %)

Operating Activities

During the year ended December

31, 2022, cash provided by operating activities was $28.9 million, aided by net income of $30.73 million.

Non-cash charges were $11.3

million and included $7.3 million in depreciation of property and equipment and right-of-use assets, $3.2 million from amortization of

intangible assets, $3.8 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable,

$8.1 million of stock compensation expense, and a non-cash loss of $2.9 million related to the impairment of a business unit that was

discontinued at the end of the year.

These charges were partially offset by non-cash gains of $1.4 million relating to the remeasurement

of finance lease liabilities $1.1 million from the remeasurement of warrant liabilities, $1.6 million in a gain on a bargain purchase

and $9.9 million in the realization of a deferred tax asset.

Changes in assets and liabilities resulted in an approximately $13.2 million

decrease to operating cash flow, as an $8.4 million increase in accounts receivable, a $4.2 million increase in prepaid expenses and a

$6.0 million decrease in accrued liabilities outweighed the effect of a $1.8 million decrease in other assets and a $3.6 million increase

in accounts payable.

During the year ended December

31, 2021, cash used in operating activities was $1.9 million, despite net income of $19.2 million.

Non-cash charges amounted to $7.7 million,

as $5.2 million in depreciation of property and equipment and right-of-use assets, $1.8 million from amortization of intangible assets,

$4.5 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable and $1.4 million of

stock compensation expense were partially offset by $5.2 million in a non-cash gain on the remeasurement of warrant liabilities.

in assets and liabilities resulted in an approximately $28.8 million decrease in operating cash flow and were primarily driven by a $57.1

million increase in accounts receivable arising from the growth of the business, particularly in the fourth quarter of the year and the

inclusion of larger Mobile Health customers with extended credit terms;

and a $3.5 million increase in prepaid expenses and other current

assets, partially offset by a $32.6 million increase in accounts payable and accrued expenses due primarily to the extension of credit

and timing of payments, as DocGo attempted to align the timing of payments to vendors with the timing of payments received from customers,

where possible, in an attempt to manage cash balances.

During the year ended December 31, 2023, cash used by operating activities was $64.2 million, despite net income of $10.0 million.

Non-cash charges amounted to $38.9 million, which primarily consisted of $11.2 million in depreciation of property and equipment and right-of-use assets, $5.2 million from amortization of intangible assets, $21.0 million of stock compensation expense, a $0.9 million loss on the disposal of assets and a loss of $0.3 million from an investment that is accounted for under the equity method and $3.6 million in bad debt expense.

These were partially offset by $2.0 million in deferred taxes and a non-cash gain of $1.4 million resulting from a reduction in the fair value of contingent consideration.

Changes in assets and liabilities resulted in approximately $113.1 million in negative operating cash flow, as a $160.5 million increase in accounts receivable, reflecting the growth of the business and primarily driven by an increased amount of business with municipalities, which tend to have longer payment cycles;

a $1.8 million decrease in accounts payable;

and a $10.8 million increase in prepaid expenses and other current assets were partially offset by a $59.0 million increase in accrued liabilities and a $1.0 million decline in other assets.

During the year ended December 31, 2022, cash provided by operating activities was $28.9 million, aided by net income of $30.7 million.

Non-cash charges were $11.3 million and included $7.3 million in depreciation of property and equipment and right-of-use assets, $3.2 million from amortization of intangible assets, $3.8 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable, $8.1 million of stock compensation expense and a non-cash loss of $2.9 million related to the impairment of a business unit that was discontinued at the end of the year.

These charges were partially offset by non-cash gains of $1.4 million relating to the remeasurement of finance lease liabilities, $1.1 million from the remeasurement of warrant liabilities, $1.6 million in a gain on a bargain purchase and $9.9 million in the realization of a deferred tax asset.

Changes in assets and liabilities resulted in an approximately $13.2 million decrease to operating cash flow, as an $8.4 million increase in accounts receivable, a $4.2 million increase in prepaid

expenses and a $6.0 million decrease in accrued liabilities outweighed the effect of a $1.8 million decrease in other assets and a $3.6 million increase in accounts payable.

During the year ended December 31, 2021, cash used in operating activities was $1.9 million, despite net income of $19.2 million.

Non-cash charges amounted to $7.7 million, as $5.2 million in depreciation of property and equipment and right-of-use assets, $1.8 million from amortization of intangible assets, $4.5 million in bad debt expense primarily related to a provision for potential uncollectible accounts receivable and $1.4 million of stock compensation expense were partially offset by $5.2 million in a non-cash gain on the remeasurement of warrant liabilities.

Changes in assets and liabilities resulted in an approximately $28.8 million decrease in operating cash flow and were primarily driven by a $57.1 million increase in accounts receivable arising from the growth of the business, particularly in the fourth quarter of the year, and the inclusion of larger Mobile Health Services customers with extended credit terms, and a $3.5 million increase in prepaid expenses and other current assets, partially offset by a $32.6 million increase in accounts payable and accrued expenses due primarily to the extension of credit and timing of payments, as DocGo attempted to align the timing of payments to vendors with the timing of payments received from customers, where possible, in an attempt to manage cash balances.

Investing Activities

During the year ended December

31, 2022, cash used in investing activities was $38.4 million and consisted of the acquisition of property and equipment totaling approximately

$3.2 million, the acquisition of intangibles in the amount of $2.3 million and $33.0 million in the acquisition of businesses, primarily

relating to acquisitions the Company completed in the third and fourth quarters of 2022.

During the year ended December

31, 2021, cash used in investing activities was $8.6 million, primarily consisting of the acquisition of property and equipment totaling

$4.8 million and the acquisition of businesses and intangibles of $3.1 million to support the ongoing growth of the business.

the Company made an equity investment amounting to approximately $0.7 million.

During the year ended December 31, 2023, investing activities used $29.9 million of cash and consisted of the acquisition of property and equipment totaling approximately $7.6 million, the acquisition of intangibles in the amount of $2.5 million, the acquisition of businesses in the amount of $20.2 million and an equity method investment in the amount of $0.3 million, partially offset by $0.7 million in cash proceeds from the disposal of property and equipment.

During the year ended December 31, 2022, cash used in investing activities was $38.4 million and consisted of the acquisition of property and equipment totaling approximately $3.2 million, the acquisition of intangibles in the amount of $2.3 million and the acquisition of businesses in the amount of $33.0 million, primarily relating to acquisitions the Company completed in the third and fourth quarters of 2022.

During the year ended December 31, 2021, cash used in investing activities was $8.6 million, primarily consisting of the acquisition of property and equipment totaling $4.8 million and the acquisition of businesses and intangibles totaling $3.1 million to support the ongoing growth of the business.

In addition, the Company made an equity investment amounting to approximately $0.7 million.

Financing Activities

During the year ended December

31, 2022, cash used in financing activities was $6.2 million, including $3.7 million in the repurchase of Common Stock, $3.0 million in

payments under the terms of a finance lease, $2.5 million decrease in amounts due to seller and $0.9 million in repayments of notes payable,

which were partially offset by $2.1 million in non-controlling interest contributions and $2.0 million in proceeds from the exercise of

stock options.

During the year ended December

31, 2021, cash provided by financing activities was $155.2 million, due primarily to $158.1 million in proceeds from the issuance of common

stock in connection with the Motion merger, which is net of $20.0 million in issuance costs.

This was slightly offset by $2.2 million

in payments on obligations under the terms of a finance lease, and $0.5 million in expenditures to acquire the remaining 20% of the Company’s

During 2021, the Company received $8.0 million in proceeds from a revolving bank loan, which was repaid during the fourth

quarter of 2021.

Future minimum annual maturities

of notes payable as of December 31, 2022 are as follows:

Amounts in millions

During the year ended December 31, 2023, cash provided by financing activities was $1.1 million, including $25 million in proceeds from the Company’s Revolving Facility and $1.6 million in proceeds from the exercise of stock options, mostly offset by $4.3 million in payments under the terms of a finance lease, a $13.6 million decrease in amounts due to seller, $5.3 million in earnout payments on contingent liabilities and $2.3 million in payments for taxes related to shares withheld for employee taxes.

During the year ended December 31, 2022, cash used in financing activities was $6.2 million, including $3.7 million in the repurchase of Common Stock, $3.0 million in payments under the terms of a finance lease, a $2.5 million decrease in amounts due to seller and $0.9 million in repayments of notes payable, which were partially offset by $2.1 million in non-controlling interest contributions and $2.0 million in proceeds from the exercise of stock options.

During the year ended December 31, 2021, cash provided by financing activities was $155.2 million, due primarily to $158.1 million in proceeds from the issuance of Common Stock in connection with the Business Combination, which is net of $20.0 million in issuance costs.

This was slightly offset by $2.2 million in payments on obligations under the terms of a finance lease and $0.5 million in expenditures to acquire the remaining 20% of the Company’s U.K.

During 2021, the Company received $8.0 million in proceeds from a revolving bank loan, which was repaid during the fourth quarter of 2021.

Future minimum annual maturities of notes payable as of December 31, 2023 are as follows (in thousands):

Notes Payable

Total maturities 69.7

1 unchanged sentence

Long-term portion of notes payable $ 41.6

minimum lease payments under finance leases as of the year ended December 31, 2022:

Amounts in millions

Future minimum lease payments under finance leases as of the year ended December 31, 2023 are as follows (in millions):

Finance Leases

2027 and thereafter

Total future minimum lease payments 12.5

1 unchanged sentence

Present value of future minimum lease payments $ 11.4

Future minimum lease payments

under operating leases as of the year ended December 31, 2022:

Operating Leases

2027 and thereafter

Future minimum lease payments under operating leases as of the year ended December 31, 2023 are as follows (in millions):

Thereafter 0.3

Total future minimum lease payments 11.1

1 unchanged sentence

Present value of future minimum lease payments $ 10.0

Critical Accounting

Critical Accounting Policies

Basis of Presentation

The Company’s Consolidated

Financial Statements are presented in conformity with accounting principles generally accepted in the U.S.

pursuant to the rules and regulations of the SEC.

The Consolidated Financial Statements include the accounts and operations of the Company

and its wholly-owned subsidiaries.

The Company’s Consolidated Financial Statements are presented in conformity with accounting principles generally accepted in the U.S.

GAAP”) and pursuant to the rules and regulations of the SEC.

The Consolidated Financial Statements include the accounts and operations of the Company and its wholly-owned subsidiaries.

All intercompany accounts and transactions are eliminated upon consolidation.

Noncontrolling interests

(“NCI”) on the Consolidated Balance Sheets represents the portion of consolidated joint ventures and a variable interest entity

in which the Company does not have direct equity ownership.

Accounts and transactions between consolidated entities have been eliminated.

Pursuant to the Business Combination,

the merger between Motion and Ambulnz was accounted for as a reverse recapitalization in accordance with U.S.

GAAP (the “Reverse

Recapitalization”).

Under this method of accounting, Motion was treated as the “acquired” company for financial reporting

Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz

stock for the net assets of Motion, accompanied by a recapitalization.

The net assets of Motion are stated at historical cost, with no

goodwill or other intangible assets recorded.

The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization

are those of Ambulnz.

The shares of common stock and corresponding capital amounts and earnings per share available for common stockholders,

prior to the Business Combination, have been retroactively restated as shares of the Company, reflecting the exchange ratio (645.1452

to 1) established in the Business Combination.

Further, Ambulnz was determined to be the accounting acquirer in the transaction, as such,

the acquisition is considered to be a business combination under Accounting Standards Codification (“ASC”), Topic 805, Business

Combinations, (“ASC 805”) and was accounted for using the acquisition method of accounting.

Noncontrolling interests on the Consolidated Balance Sheets represents the portion of consolidated joint ventures and a variable interest entity (“VIE”) in which the Company does not have direct equity ownership.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S.

GAAP (the “Reverse Recapitalization”).

Under this method of accounting, the Company was treated as the “acquired” company for financial reporting purposes.

Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz stock for the net assets of the Company, accompanied by a recapitalization.

The net assets of the Company are stated at historical cost, with no goodwill or other intangible assets recorded.

The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz.

The shares of common stock and corresponding capital amounts and earnings per share available for common stockholders, prior to the Business Combination, have been retroactively restated as shares of the Company, reflecting the exchange ratio (645.1452 to 1) established in the Business Combination.

Further, Ambulnz was determined to be the accounting acquirer in the transaction;

as such, the acquisition is considered to be a business combination under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations and was accounted for using the acquisition method of accounting.

Principles of Consolidation

The Company holds a variable

interest in an entity which contracts with physicians and other health professionals in order to provide services to the Company.

Medical Care P.C.

(“MD1”) is considered a variable interest entity (“VIE”) since it does not have sufficient equity

to finance its activities without additional subordinated financial support.

An enterprise having a controlling financial interest in

a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of

a VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the

VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant

to the VIE (benefits).

The Company has the power and rights to control all activities of MD1 and funds and absorbs all losses of the VIE

and appropriately consolidates MD1.

Total revenue for the VIE

amounted to $2,857,463 as of December 31, 2022.

Net loss for the VIE was $373,456 as of December 31, 2022.

The VIE’s total assets,

all of which were current, amounted to $610,553 as of December 31, 2022.

Total liabilities, all of which were current for the VIE, was

$320,424 as of December 31, 2022.

The VIE’s total stockholders’ deficit was $290,130 as of December 31, 2022.

made payments of $3,018,119 and $1,746,736 to MD1 and its affiliates during the years ended December 31, 2022 and 2021, respectively.

In accordance with ASC 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are VIEs.

For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

The Company holds variable interests in legal entities that contract with physicians and other health professionals in order to provide services to the Company.

These entities are considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support.

An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is the primary beneficiary, meaning it has (1) the power to direct the activities of the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits).

The Company has the power and rights to control all activities of its VIEs and funds and absorbs all losses of its VIEs.

The Company has determined that it is the primary beneficiary of its VIEs and therefore appropriately consolidates its VIEs.

Net loss for the Company’s VIEs were $235,976, $373,456 and $122,982 for the years ended December 31, 2023, 2022 and 2021, respectively.

The total assets amounted to $4,364,274 and $610,553 on December 31, 2023 and 2022, respectively.

Total liabilities were $4,811,857 and $320,424 on December 31, 2023 and 2022, respectively.

The Company’s VIEs total stockholders’ deficit were $447,583 and $290,130 on December 31, 2023 and 2022, respectively.

Business Combinations

The Company accounts for its business combinations

under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method

of accounting be used for all business combinations.

Assets acquired and liabilities assumed, including NCI, are recorded at the date

of acquisition at their respective fair values.

ASC 805-10 also specifies criteria that intangible assets acquired in a business combination

must meet to be recognized and reported apart from goodwill.

Goodwill represents the excess purchase price

over the fair value of the tangible net assets and intangible assets acquired in a business combination.

If the business combination provides

for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in

fair value after the acquisition date are accounted for as measurement-period adjustments.

Changes in fair value of contingent consideration

resulting from events after the acquisition date, such as earn-outs, are recognized as follows:

1) if the contingent consideration is

classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or

2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings.

For transactions

that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase.

The Company capitalizes

acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated

with business combinations.

The estimated fair value of net assets to be acquired,

including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques.

The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations.

Assets acquired and liabilities assumed, including noncontrolling interests, are recorded at the date of acquisition at their respective fair values.

ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination.

If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments.

Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows:

1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings.

For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase.

The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.

The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques.

Management uses assumptions on the basis of historical knowledge of the business and projected financial information of the target.

assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management,

and such variations may be significant to estimated values.

Goodwill and Indefinite-Lived Intangible

Goodwill represents the excess

of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination.

Goodwill is not amortized but is tested for impairment at the reporting unit level annually on December 31 or more frequently if events

or changes in circumstances indicate that it is more likely than not to be impaired.

These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination.

Goodwill is not amortized but is tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired.

These events include:

(i) severe adverse industry

or economic trends;

(i) severe adverse industry or economic trends;

(ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations;

(iii) current, historical or projected deterioration of our financial performance;

or (iv) a sustained decrease in our market capitalization,

as indicated by our publicly quoted share price, below our net book value.

On February 3, 2023, Ambulnz

Health, LLC (“Health”), commenced an assignment for the benefit of creditors (“ABC”) pursuant to California law.

An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under

Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance

with California law.

In the ABC, all of Health’s assets were transferred to an assignee (the “Assignee”) who acts as

a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee.

The Assignee is responsible for liquidating the

or (iv) a sustained decrease in our market capitalization, as indicated by our publicly quoted share price, below our net book value.

On February 3, 2023, Ambulnz Health, LLC (“Health”), commenced an assignment for the benefit of creditors (“ABC”) pursuant to California law.

An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law.

Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law.

In the ABC, all of Health’s assets were transferred to an assignee (the “Assignee”) who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee.

The Assignee is responsible for liquidating the assets.

Similar to a bankruptcy case, there is a claims process.

Creditors of Health will receive notice of the ABC and a proof of claim

form and are required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.

Based on such filing for Health,

the Company impaired the goodwill assigned to that reporting unit as of December 31, 2022 by approximately $5.1 million.

Creditors of Health received notice of the ABC and a proof of claim form and were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.

Based on such filing for Health, the Company impaired the goodwill assigned to that reporting unit as of December 31, 2022 by approximately $5.1 million.

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09,

Revenue from Contracts with Customers (“ASC 606”), as amended.

To determine revenue recognition for contractual

arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps:

each contract with a customer;

On January 1, 2019, the Company adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”).

To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps:

(1) identify each contract with a customer;

(2) identify the performance obligations in the contract;

(3) determine the transaction price;

the transaction price to performance obligations in the contract;

and (5) recognize revenue when (or as) the relevant performance obligation

is satisfied.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration

it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) ambulance

and medical transportation services (“Transportation Services”) and (2) Mobile Health services.

The customer simultaneously

receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies

performance obligations immediately.

The Company has utilized the “right to invoice” expedient which allows an entity to recognize

revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to

invoice corresponds directly to the value transferred to the customer.

Revenues are recorded net of an estimated contractual allowances

for claims subject to contracts with responsible paying entities.

The Company estimates contractual allowances at the time of billing

based on contractual terms, historical collections, or other arrangements.

All transaction prices are fixed and determinable which includes

a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payor.

Income taxes are recorded in accordance with ASC

740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach.

recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial

statements or its tax returns.

Deferred tax assets and liabilities are determined based on the difference between the financial statement

and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the

deferred tax assets will not be realized.

(4) allocate the transaction price to performance obligations in the contract;

and (5) recognize revenue when (or as) the relevant performance obligation is satisfied.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) Mobile Health Services and (2) Transportation Services.

The customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled;

therefore the Company satisfies performance obligations immediately.

The Company has utilized the “right to invoice” expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer.

Revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities.

The Company estimates contractual allowances at the time of billing based on contractual terms, historical collections or other arrangements.

All transaction prices are fixed and determinable, which includes a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payor.

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach.

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns.

Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more

likely than not be realized assuming examination by the taxing authority.

The determination as to whether the tax benefit will more likely

than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority.

The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

Please see Note 2, “Summary

of Significant Accounting Policies” to the Consolidated Financial Statements.

and Qualitative Disclosures About Market Risk.

We are a smaller reporting

company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required

to provide the information under this item.

Please see Note 2, “Summary of Significant Accounting Policies” to the Consolidated Financial Statements.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 7. Management’s Discussion and Analysis